T1	Participants 108 145	patients with gastrointestinal cancer
T2	Participants 417 454	patients with gastrointestinal cancer
T3	Participants 703 818	5-year survival and cancer recurrence among 512 patients with gastrointestinal cancer included in the TACTIC study.
T4	Participants 832 1005	89.2 per cent of patients had a primary tumour and 79.7 per cent underwent surgery with curative intent; 243 patients received perioperative RBC transfusion (median 3 units)
T5	Participants 1007 1176	The 5-year overall survival rate of patients with any type of gastrointestinal cancer was 50.8 per cent in the LD group and 45.8 per cent in the non-LD group (P = 0.191)
T6	Participants 1192 1324	5-year disease-free survival rates were 60.0 and 56.6 per cent (P = 0.482), and recurrence rates 32.9 and 34.3 per cent (P = 0.864).
